<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week&apos;s episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the &apos;biotech winter,&apos; closing a $700 million upfront licensing deal with AbbVie, the impact of China&apos;s rising biotech sector, and the keys to successful collaboration. Cyril also discusses IGI&apos;s focus on developing innovative therapies for emerging markets, and the shift from animal models to in silico modeling in preclinical research.   Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;On this week&amp;apos;s episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the &amp;apos;biotech winter,&amp;apos; closing a $700 million upfront licensing deal with AbbVie, the impact of China&amp;apos;s rising biotech sector, and the keys to successful collaboration. Cyril also discusses IGI&amp;apos;s focus on developing innovative therapies for emerging markets, and the shift from animal models to in silico modeling in preclinical research.   &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million upfront licensing deal with AbbVie, the impact of China's rising biotech sector, and the keys to successful collaboration. Cyril also discusses IGI's focus on developing innovative therapies for em...

Biotech Collaboration Strategy With IGI's Cyril Konto, M.D.

<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market. We discuss the implications of recent blockbuster acquisitions, strategies for managing the current funding environment for biotech, what to look for in the IPO market in the coming months, alternative financing opportunities, and what besides lower interest rates might bring generalist investors back into the sector. Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market. We discuss the implications of recent blockbuster acquisitions, strategies for managing the current funding environment for biotech, what to look for in the IPO market in the coming months, alternative financing opportunities, and what besides lower interest rates might bring generalist investors back into the sector. &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market. We discuss the implications of recent blockbuster acquisitions, strategies for managing the current funding environment for biotech, what to look for in the IPO market in the coming months, alternative financing opportunities, and what besides low...

Biotech Funding And IPO Temperature Check With Create Medicine's Allan Shaw

<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week&apos;s episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. Mardi describes how drug companies transition from an R&amp;D focus to commercializing products, how to read IPO windows and manage expectations, pricing new drugs, and balancing commercial efforts with pipeline renewal and maintenance. Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;On this week&amp;apos;s episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. Mardi describes how drug companies transition from an R&amp;amp;D focus to commercializing products, how to read IPO windows and manage expectations, pricing new drugs, and balancing commercial efforts with pipeline renewal and maintenance. &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. Mardi describes how drug companies transition from an R&amp;D focus to commercializing products, how to read IPO windows and manage expectations, pricing new drugs, and balancing commer...

Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier

<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week&apos;s episode of the Business of Biotech, we&apos;re speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to develop an oral candidate for dystonia, a movement disorder. Ravina talks about transitioning from government and academic medicine to industry, partnering with Atlas Ventures and defining the company&apos;s thesis, the reasons behind working in stealth mode and when to emerge, and the clinical plan and potential for VIM0423.  Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;On this week&amp;apos;s episode of the Business of Biotech, we&amp;apos;re speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to develop an oral candidate for dystonia, a movement disorder. Ravina talks about transitioning from government and academic medicine to industry, partnering with Atlas Ventures and defining the company&amp;apos;s thesis, the reasons behind working in stealth mode and when to emerge, and the clinical plan and potential for VIM0423.  &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to develop an oral candidate for dystonia, a movement disorder. Ravina talks about transitioning from government and academic medicine to industry, partnering with Atlas Ventures and defining the company's thesis, the reasons behind working in...

Emerging From Stealth With Vima Therapeutics' Bernard Ravina, M.D.

<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week&apos;s episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Science Leader&apos;s editorial advisory board and Miami-based location host for our in-person series. Rich talks about Catalyst&apos;s rare disease strategy built on operational excellence (including how to select a rare disease special pharmacy), his criteria for selecting de-risked, differentiated, and accretive products for rare diseases, partnering outside the U.S., and what new incentives Florida politicians could create to help South Florida grow even faster as a life sciences hub. Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;On this week&amp;apos;s episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of &lt;em&gt;Life Science Leader&amp;apos;s&lt;/em&gt; editorial advisory board and Miami-based location host for our in-person series. Rich talks about Catalyst&amp;apos;s rare disease strategy built on operational excellence (including how to select a rare disease special pharmacy), his criteria for selecting de-risked, differentiated, and accretive products for rare diseases, partnering outside the U.S., and what new incentives Florida politicians could create to help South Florida grow even faster as a life sciences hub. &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  On this week's episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Science Leader's editorial advisory board and Miami-based location host for our in-person series. Rich talks about Catalyst's rare disease strategy built on operational excellence (including how to select a rare disease special pharmacy), his criteria for selecting de-risked, d...

BoB in South Florida: Rich Daly, Catalyst Pharmaceuticals

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.

Business Of Biotech

Details

Recent Episodes